The positively charged nanoparticle polyamidoamine generation 3 (P-G3) can be specifically targeted to either visceral or subcutaneous fat, and affects both types of fat in different ways, researchers from Columbia University reported in two papers recently published. The studies, published online in Nature Nanotechnology on Dec. 1, 2022, and in Biomaterials on Nov. 28, 2022, are both “a conceptual advance” and “quite amenable to translation,” co-corresponding author Kam Leong told BioWorld. Read More
When a drug prevents bacteria from synthesizing their own folate, an essential compound for their survival, they take it directly from the host. This antibiotic resistance mechanism had not been detected until now because bacteria behave differently in the laboratory than they do in vivo during an infection. Read More
Researchers from Nalo Therapeutics Inc. presented the discovery and preclinical evaluation of a novel orally bioavailable and brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, NX-019, being developed as a potential therapeutic agent to treat EGFR-mutant solid tumors. Read More
Previous research has shown that cytotoxic lymphocytes rely on gasdermin-mediated pyroptosis to kill tumor cells. Pyroptosis appears to be closely involved in anticancer immune response and has therefore emerged as a promising strategy for cancer treatment. In a recently published study, scientists at the University of Wisconsin-Madison aimed to leverage gasdermin-triggered pyroptosis for antitumor immunotherapy. Read More
Research conducted at Inflection Biosciences Ltd. and affiliated organizations has led to the discovery of a novel pan-PIM kinase inhibitor, IBL-101, as a potential therapeutic candidate for autoimmune disease, including psoriasis. Read More
In accordance with the publishing schedule, BioWorld Science was not published on Tuesday, Dec. 6, 2022, and will not be published on Thursday, Dec. 8, 2022. Read More
A research team based at the University of California, San Diego presented data from a study that evaluated the novel cyclophilin D (CypD) inhibitor CC-2055 in preclinical models of epilepsy. Read More
Tonix Pharmaceuticals Holding Corp. has entered into a sponsored research agreement with Boston Children's Hospital to study TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, for the prevention of graft-vs.-host disease (GVHD) after hematopoietic stem cell transplant (HSCT) in animals. Read More
Aviceda Therapeutics LLC has completed IND-enabling good laboratory practice (GLP) toxicity studies of its lead ophthalmic drug candidate, AVD-104, in nonhuman primates and rabbits. Read More
Abbvie Inc. and Hotspot Therapeutics Inc. have entered into an exclusive worldwide collaboration and option to license agreement for Hotspot's discovery-stage interferon regulatory factor 5 (IRF5) program for the treatment of autoimmune diseases. Read More
NK cell-based cancer immunotherapy has emerged as an anticancer treatment approach and is currently being tested in clinical trials. KIR2DL5, a member of the human killer cell immunoglobulin-like receptor (KIR) family, has recently been identified as a binding partner for poliovirus receptor (PVR). However, the biology and therapeutic potential of the KIR2DL5/PVR pathway remain widely unexplored. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its partnership with VBI Vaccines Inc. to advance the development of multivalent coronavirus vaccines that could be deployed against COVID-19 and possible future coronaviruses with pandemic potential, referred to as coronavirus X. Read More
Chengdu Baiyu Pharmaceutical Co. Ltd. has disclosed NLRP3 inflammasome inhibitors acting as pyroptosis inhibitors reported to be useful for the treatment of gout, Alzheimer's disease, atherosclerosis, diabetes, psoriasis, rheumatoid arthritis, graft-vs.-host disease and familial cold urticaria syndrome. Read More
Cgenetech (Suzhou, China) Co. Ltd. has synthesized ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer. Read More
Pfizer Inc. and Clear Creek Bio Inc. have entered into a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. Read More
Glycomimetics Inc. has identified glycosides acting as galectin 3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, inflammation, thrombosis, cardiovascular disorders, transplant rejection, neurodegeneration, fibrosis and liver diseases, among other disorders. Read More
Sinovent Inc. has divulged nitrogen-containing heterocyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer. Read More
Tetra Bio-Pharma Inc. has reported results from a study of ARDS-003 (onternabez) combined with favipiravir against acute respiratory distress syndrome (ARDS), sepsis and COVID-19 through PREPAiRE, an artificial intelligence (AI)-powered platform which integrates target identification, validation, lead discovery optimization, drug synthesis and preclinical testing. Read More
Oric Pharmaceuticals Inc. has described serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer. Read More
